Pharmaceutical Composition for Preventing Heart Disease and Pulmonary Hypertension in Animals
Summary
CARESIDE CO., LTD. has published patent application US20260108532A1, filed September 6, 2023, covering a pharmaceutical composition for preventing and treating heart disease and pulmonary hypertension in animals. The composition includes the active pharmaceutical ingredients pimobendan, enalapril, torsemide, and spironolactone. The application was published on April 23, 2026, under CPC classifications A61K and A61P relating to pharmaceutical preparations for cardiovascular conditions.
“The composition includes pimobendan, enalapril, torsemide, and spironolactone, and is thus effective in preventing and treating heart disease and pulmonary hypertension of animals.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO patent application US20260108532A1 has been published covering a pharmaceutical composition for preventing and treating heart disease caused by pulmonary hypertension in animals. The composition comprises four active ingredients: pimobendan, enalapril, torsemide, and spironolactone. If granted, the patent would provide CARESIDE CO., LTD. with intellectual property protection for this veterinary cardiovascular formulation. Competitors developing similar animal heart disease treatments should be aware of this published application when designing around potential claims.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITION FOR PREVENTING HEART DISEASES CAUSED BY PULMONARY HYPERTENSION AND TREATING HEART, AND FUNCTIONAL FORMULATION COMPRISING SAME
Application US20260108532A1 Kind: A1 Apr 23, 2026
Assignee
CARESIDE CO., LTD.
Inventors
Young Kook YOU
Abstract
There are provided a composition for preventing and treating heart disease due to pulmonary hypertension, and a functional preparation containing the same. The composition includes pimobendan, enalapril, torsemide, and spironolactone, and is thus effective in preventing and treating heart disease and pulmonary hypertension of animals.
CPC Classifications
A61K 31/585 A61K 31/44 A61K 31/501 A61K 38/05 A61P 9/04 A61P 9/12
Filing Date
2023-09-06
Application No.
19152793
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.